Europäischer Markt für Dyspepsiemedikamente – Branchentrends und Prognose bis 2030

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Europäischer Markt für Dyspepsiemedikamente – Branchentrends und Prognose bis 2030

  • Pharmaceutical
  • Publish Reports
  • May 2023
  • Europe
  • 350 Seiten
  • Anzahl der Tabellen: 573
  • Anzahl der Abbildungen: 52

Europe Dyspepsia Drug Market

Marktgröße in Milliarden USD

CAGR :  % Diagram

Diagramm Prognosezeitraum
2024 –2030
Diagramm Marktgröße (Basisjahr)
MILLIONEN USD
Diagramm Marktgröße (Prognosejahr)
MILLIONEN USD
Diagramm CAGR
%
Diagramm Wichtige Marktteilnehmer
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Europäischer Markt für Dyspepsie-Medikamente nach Typ (organische Dyspepsie, nicht-ulzerative Dyspepsie, medikamenteninduzierte Dyspepsie und andere), Behandlungsart (medikamentös und chirurgisch), Medikamententyp (Marken- und Generika), Verschreibung (ohne Rezept und verschreibungspflichtige Medikamente), Verabreichungsweg (oral und injizierbar), Geschlecht (männlich und weiblich), Endverbraucher (Krankenhäuser, Kliniken, Einrichtungen der häuslichen Pflege, Fachkliniken, ambulante chirurgische Zentren , akademische und staatliche Forschungsinstitute und andere), Vertriebskanal (direkte Ausschreibung und Einzelhandelsverkauf) – Branchentrends und Prognose bis 2030.

Europäischer Markt für Dyspepsiemedikamente

Marktanalyse und Einblicke für Dyspepsiemedikamente in Europa

Der europäische Markt für Dyspepsiemedikamente dürfte im Prognosezeitraum aufgrund der zunehmenden Verbreitung von Dyspepsie und der zunehmenden Annahme ungesunder Lebensgewohnheiten wachsen. Der Markt wird auch durch die zunehmende Verbreitung von Stoffwechselstörungen beeinflusst. Der europäische Markt für Dyspepsiemedikamente dürfte jedoch durch die möglichen Nebenwirkungen der gegen Dyspepsie eingesetzten Medikamente und die zunehmende Präferenz für natürliche und pflanzliche Heilmittel beeinträchtigt werden. Die zunehmende Alterung der Bevölkerung und die Zunahme der Arzneimittelzulassungen dürften Chancen für das Marktwachstum bieten. Strenge Vorschriften und ein mangelndes Bewusstsein der Bevölkerung für Dyspepsie dürften jedoch das Marktwachstum behindern.

Europäischer Markt für DyspepsiemedikamenteEuropäischer Markt für Dyspepsiemedikamente

Laut einer Analyse von Data Bridge Market Research wird der europäische Markt für Dyspepsiemedikamente im Prognosezeitraum von 2023 bis 2030 voraussichtlich mit einer durchschnittlichen jährlichen Wachstumsrate von 4,7 % wachsen.

Berichtsmetrik

Details

Prognosezeitraum

2023 bis 2030

Basisjahr

2022

Historische Jahre

2021 (Anpassbar auf 2015 – 2020)

Quantitative Einheiten

Umsatz in Tausend, Mengen in Einheiten und Preise in USD

Abgedeckte Segmente

Typ (Organische Dyspepsie, Nicht-Ulkus-Dyspepsie, Arzneimittelinduzierte Dyspepsie und andere), Behandlungstyp (Medikamente und Operationen), Arzneimitteltyp (Marken- und Generika), Verschreibung (ohne und mit verschreibungspflichtigen Arzneimitteln), Verabreichungsweg (oral und injizierbar), Geschlecht (männlich und weiblich), Endverbraucher (Krankenhäuser, Kliniken, häusliche Pflegeeinrichtungen, Fachkliniken, ambulante chirurgische Zentren, akademische und staatliche Forschungsinstitute und andere), Vertriebskanal (direkte Ausschreibung und Einzelhandelsverkauf)

Abgedeckte Länder

Deutschland, Großbritannien, Frankreich, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei, Belgien, Dänemark, Schweden, Polen, Norwegen, Finnland und Rest von Europa

Abgedeckte Marktteilnehmer

Bayer AG, Cadila Pharmaceuticals, Sanofi, Lupin, Abbott, Perrigo Company plc, AstraZeneca, Procter & Gamble und Reckitt Benckiser unter anderem

Marktdefinition

Dyspepsie, allgemein bekannt als Verdauungsstörung, ist der Schmerz und das Unbehagen im Bauch nach dem Essen. Es ist normalerweise ein Zeichen einer zugrunde liegenden Erkrankung wie GERD (gastroösophageale Refluxkrankheit), Gallenblasen- und Geschwürerkrankung. Die Behandlung von Dyspepsie hängt von der Ursache und dem Schweregrad ab. Die Behandlung einer zugrunde liegenden Erkrankung oder eine Änderung der Medikamente einer Person kann die Dyspepsie reduzieren. Dyspepsie wird in zwei Hauptkategorien unterteilt: „organische“ und „funktionelle Dyspepsie“ (FD). Organische Ursachen für Dyspepsie sind Magengeschwüre, gastroösophageale Refluxkrankheit, Magen- oder Speiseröhrenkrebs, Bauchspeicheldrüsen- oder Gallenerkrankungen, Nahrungsmittel- oder Arzneimittelunverträglichkeiten und andere infektiöse oder systemische Erkrankungen. Funktionelle Dyspepsie (dis-PEP-see-uh) ist ein Begriff für wiederkehrende Symptome einer Magenverstimmung, die keine offensichtliche Ursache haben. Funktionelle Dyspepsie wird auch als nicht-ulzeröse Dyspepsie bezeichnet.

Dynamik des europäischen Marktes für Dyspepsiemedikamente

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:

TREIBER

  • Zunehmende Prävalenz von Dyspepsie

Dyspepsie, allgemein als Verdauungsstörung bekannt, ist eine Magen-Darm-Störung, die Millionen von Menschen in Europa betrifft. Es handelt sich um eine Erkrankung, die Unbehagen, Schmerzen und ein Völlegefühl oder Blähungen im Oberbauch verursacht. Dyspepsie kann durch eine Vielzahl von Faktoren verursacht werden, wie z. B. zu schnelles Essen, den Verzehr von scharfen oder fettigen Speisen oder als Nebenwirkung von Medikamenten.

Die zunehmende Verbreitung von Dyspepsie ist einer der wichtigsten Antriebsfaktoren für das Wachstum des Marktes für Dyspepsie-Medikamente. Die steigende Inzidenz von Dyspepsie kann auf mehrere Faktoren zurückgeführt werden, wie etwa Veränderungen des Lebensstils, der Ernährungsgewohnheiten und eine alternde Bevölkerung. Mit zunehmendem Alter sind Menschen anfälliger für Verdauungsprobleme, einschließlich Dyspepsie. Mit der wachsenden Zahl älterer Erwachsener steigt die Nachfrage nach Dyspepsie-Medikamenten.

Darüber hinaus verursachen auch verschiedene Verdauungskrankheiten wie Reizdarmsyndrom, Gastroparese, Gastritis und Magengeschwüre Dyspepsie, da die Prävalenz der genannten Krankheiten zunimmt. Daher wird erwartet, dass die zunehmende Prävalenz von Dyspepsie und anderen Verdauungsstörungen, die Dyspepsie verursachen, als Wachstumsmotor für den Markt fungiert. Der Einsatz von Dyspepsie-Medikamenten zur Linderung der Symptome von Dyspepsie und zur Behandlung der Dyspepsie hat das Potenzial, die Behandlungsergebnisse der Patienten zu verbessern und die Belastung durch Dyspepsie zu verringern. Daher treibt die zunehmende Prävalenz von Dyspepsie die Nachfrage nach Dyspepsie-Medikamenten weltweit an, um die Inzidenz und Prävalenz der Dyspepsie in der Bevölkerung zu erhöhen.

  • Anstieg der Annahme eines ungesunden Lebensstils

In den letzten Jahren hat die Annahme eines ungesunden Lebensstils zugenommen, was zu einer Zunahme der Dyspepsie geführt hat. Ungesunde Lebensgewohnheiten wie eine Ernährung mit hohem Anteil verarbeiteter Lebensmittel, Bewegungsmangel und übermäßiger Alkoholkonsum können alle zu Dyspepsie beitragen.

Infolgedessen ist die Nachfrage nach Dyspepsie-Medikamenten entsprechend gestiegen, da die Menschen nach Linderung ihrer Symptome suchen. Der Markt für Dyspepsie-Medikamente hat auf diese Nachfrage mit einer Vielzahl von Medikamenten reagiert, darunter Protonenpumpenhemmer, H2-Rezeptorantagonisten und Antazida.

Der Anstieg ungesunder Lebensgewohnheiten kann auf mehrere Faktoren zurückgeführt werden, darunter veränderte Ernährungsgewohnheiten, steigende Stresslevel und eine sitzende Lebensweise. Das moderne Leben ist oft durch lange Arbeitszeiten, hohe Stresslevel und den einfachen Zugang zu Fast Food und anderen ungesunden Optionen gekennzeichnet. Diese Faktoren können zu Dyspepsie und anderen damit verbundenen Erkrankungen wie der gastroösophagealen Refluxkrankheit (GERD) beitragen.

Zusammenfassend lässt sich sagen, dass Dyspepsie eine weit verbreitete Erkrankung ist, die durch eine Vielzahl von Faktoren verursacht werden kann, darunter auch ungesunde Lebensgewohnheiten. Die zunehmende Annahme ungesunder Lebensgewohnheiten hat zu einer Zunahme der Dyspepsie-Prävalenz beigetragen, und die Nachfrage nach wirksamen Dyspepsie-Medikamenten ist entsprechend gestiegen, was voraussichtlich als Wachstumsmotor für den Markt wirken wird.

GELEGENHEIT

  • Wachsende, alternde Bevölkerung

Schätzungen zufolge wird die Zahl der über 65-jährigen Menschen bis zum Jahr 2050 voraussichtlich 1,5 Milliarden erreichen. Dies zeigt, dass die Weltbevölkerung rasch altert und immer älter wird. Mit zunehmendem Alter steigt das Risiko, chronische Erkrankungen zu entwickeln. Dazu gehören Verdauungsstörungen wie Dyspepsie, die als Folge des Alterns auftreten können.

Die wachsende und alternde Bevölkerung bietet erhebliche Chancen für eine Ausweitung des Marktes für Dyspepsie-Medikamente. Da immer mehr Menschen Probleme mit ihrem Verdauungssystem haben, besteht ein wachsender Bedarf an wirksamen Behandlungen, die die Schwere ihrer Symptome verringern und ihre allgemeine Lebensqualität verbessern können.

Darüber hinaus muss die Behandlung von Dyspepsie möglicherweise speziell auf die Anforderungen einer alternden Bevölkerung zugeschnitten werden. Ältere Menschen können mehrere chronische Erkrankungen haben und gleichzeitig mehrere Medikamente einnehmen, was die Wahrscheinlichkeit negativer Wechselwirkungen und Nebenwirkungen erhöhen kann. Daher besteht ein Bedarf an Medikamenten gegen Dyspepsie, die bei der Verabreichung an ältere Erwachsene sowohl risikofrei als auch wirksam sind. Und mit zunehmendem Alter verlieren Menschen auch ihre körperliche Stärke und ihr Immunsystem, was zu einer zunehmenden Verbreitung mehrerer Magen-Darm-Erkrankungen, einschließlich Dyspepsie, führt.

Daher ist zu erwarten, dass die zunehmende Alterung der Bevölkerung, die zu Dyspepsie und deren Symptomen führt, und die Vorliebe der Menschen für vorbeugende Gesundheitsfürsorge Chancen für das Wachstum des Marktes für Dyspepsie-Medikamente bieten werden.

ZURÜCKHALTUNG/HERAUSFORDERUNG

  • Mangelndes Bewusstsein für Dyspepsie in der Bevölkerung

Der Fachkräftemangel wirkt sich bereits jetzt auf das Land aus, da immer mehr Menschen mehr als sechs Monate auf ihre zahnärztliche Behandlung warten müssen. Aufgrund des technischen Fortschritts, der grundlegenden Infrastruktur und mehrerer anderer Faktoren herrscht in Schwellen- oder Entwicklungsländern ein Mangel an qualifizierten Fachkräften auf dem Gebiet der Dyspepsie-Medikamente.

Der Mangel an qualifizierten Fachkräften ist teilweise auf die strenge Ausbildung und das Training zurückzuführen, die erforderlich sind, um ein Zahnarzt zu werden, sowie auf den wettbewerbsintensiven Arbeitsmarkt. Darüber hinaus benötigen qualifizierte Zahnärzte mehr offiziell ausgebildete, zugelassene Zahnarzthelfer, um den Zugang zur Zahnpflege aufrechtzuerhalten und zu verbessern, damit diese fortschrittliche technologische Systeme wie Dyspepsie-Medikamentensysteme bedienen und ausführen können.

In den Schwellenländern mangelt es an qualifizierten Fachkräften, die die neuen Technologien nicht effektiv einsetzen können. Dies könnte zu einer Herausforderung auf dem Markt für neue Technologien führen, da diese Länder den Beginn technologisch getriebener Fortschritte auf dem Markt verzögern.

Jüngste Entwicklungen

  • Im April 2023 gab Sanofi den Abschluss der Übernahme von Prevention Bio, Inc. bekannt. Diese Übernahme hat dem Unternehmen beim Ausbau seines Geschäfts im Bereich Allgemeinmedizin geholfen.
  • Im Juli 2022 gab ANI Pharmaceuticals, Inc. den Kauf von vier verkürzten Anträgen auf Zulassung neuer Arzneimittel (ANDAs) von Oakrum Pharma, LLC, einem privaten biopharmazeutischen Unternehmen, bekannt.

Marktsegmentierung für Dyspepsiemedikamente in Europa

Der europäische Markt für Dyspepsiemedikamente ist nach Typ, Behandlungsart, Medikamententyp, Verschreibung, Verabreichungsweg, Geschlecht, Endverbraucher und Vertriebskanal segmentiert. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Nischenwachstumsbereichen und Strategien zur Marktbearbeitung und zur Bestimmung Ihrer Hauptanwendungsbereiche und der Unterschiede in Ihren Zielmärkten.

Typ

  • Nicht-ulzeröse Dyspepsie
  •  Organische Dyspepsie
  •  Arzneimittelinduzierte Dyspepsie
  •  Sonstiges

Je nach Typ ist der europäische Markt für Dyspepsiemedikamente in organische Dyspepsie, nicht-ulzerative Dyspepsie, medikamenteninduzierte Dyspepsie und andere unterteilt.

Behandlungstyp

  • Medikamente
  • Operation

Basierend auf der Behandlungsart ist der europäische Markt für Dyspepsiemedikamente in medikamentöse und chirurgische Eingriffe unterteilt.

Arzneimitteltyp

  • Gebrandmarkt
  • Generisch

Basierend auf dem Arzneimitteltyp ist der europäische Markt für Dyspepsiemedikamente in Generika und Markenmedikamente unterteilt.

Rezept

  • Ohne verschreibungspflichtige Medikamente
  • Verschreibungspflichtige Medikamente

Basierend auf der Verschreibung ist der europäische Markt für Dyspepsiemedikamente in rezeptfreie und rezeptpflichtige Medikamente segmentiert.

Verabreichungsweg

  • Oral
  • Injektion

Basierend auf der Verabreichungsart ist der europäische Markt für Dyspepsiemedikamente in orale und injizierbare Medikamente unterteilt.

Geschlecht

  • Männlich
  • Weiblich

Basierend auf dem Geschlecht ist der europäische Markt für Dyspepsiemedikamente in männlich und weiblich unterteilt.

Endbenutzer

  • Krankenhäuser
  • Kliniken
  • Einstellungen für die häusliche Pflege
  • Spezialkliniken
  • Ambulante Zentren
  • Akademische und staatliche Forschungsinstitute
  • Sonstiges

Basierend auf dem Endverbraucher ist der europäische Markt für Dyspepsiemedikamente in Krankenhäuser, Kliniken, Einrichtungen der häuslichen Pflege, Fachkliniken, ambulante chirurgische Zentren, akademische und staatliche Forschungsinstitute und andere unterteilt.

Vertriebskanal

  • Direkte Ausschreibung
  • Einzelhandelsumsätze

Basierend auf dem Vertriebskanal ist der europäische Markt für Dyspepsiemedikamente in Direktausschreibungen und Einzelhandelsverkäufe segmentiert.

Markt für Dyspepsie-Medikamente

Europa: Regionale Analyse/Einblicke zum Markt für Dyspepsiemedikamente

Der europäische Markt für Dyspepsiemedikamente wird analysiert und es werden Erkenntnisse und Trends zur Marktgröße basierend auf Typ, Behandlungsart, Medikamententyp, Verschreibung, Verabreichungsweg, Geschlecht, Endverbraucher und Vertriebskanal bereitgestellt.

Die in diesem Marktbericht abgedeckten Länder sind Deutschland, Großbritannien, Frankreich, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei, Belgien, Dänemark, Schweden, Polen, Norwegen, Finnland und der Rest von Europa.

Aufgrund der zunehmenden Technologie und Zuverlässigkeit der Gesundheitsdienste wird Deutschland voraussichtlich den europäischen Markt für Dyspepsiemedikamente dominieren. Die Nachfrage in dieser Region wird voraussichtlich durch einen Anstieg der Dyspepsie aufgrund der zunehmenden Alterung der Bevölkerung angetrieben.

Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunkte wie die Analyse der nachgelagerten und vorgelagerten Wertschöpfungskette, technische Trends, Porters Fünf-Kräfte-Analyse und Fallstudien sind einige der Hinweise, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung einer Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit europäischer Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.

Wettbewerbsumfeld und Analyse der Marktanteile von Dyspepsiemedikamenten in Europa

Die Wettbewerbslandschaft des europäischen Marktes für Dyspepsiemedikamente liefert Einzelheiten zu den Wettbewerbern. Zu den enthaltenen Einzelheiten gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz in Europa, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den Markt.

Zu den wichtigsten Marktteilnehmern auf diesem Markt zählen unter anderem Bayer AG, Cadila Pharmaceuticals, Sanofi, Lupin, Abbott, Perrigo Company plc, AstraZeneca, Procter & Gamble und Reckitt Benckiser.


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE DYSPEPSIA DRUG MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END-USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 EPIDEMIOLOGY

6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA

7 INDUSTRY INSIGHTS:

8 EUROPE DYSPEPSIA DRUG MARKET, REGULATION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 INCREASING PREVALENCE OF DYSPEPSIA

9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE

9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS

9.2 RESTRAINTS

9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA

9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES

9.3 OPPORTUNITIES

9.3.1 GROWING AGING POPULATION

9.3.2 RISE IN THE DRUG APPROVAL

9.4 CHALLENGES

9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION

9.4.2 STRINGENT REGULATIONS

10 EUROPE DYSPEPSIA DRUG MARKET, BY TYPE

10.1 OVERVIEW

10.2 NON-ULCER DYSPEPSIA

10.3 ORGANIC DYSPEPSIA

10.4 DRUG INDUCED DYSPEPSIA

10.5 OTHERS

11 EUROPE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 DRUGS

11.2.1.1 ANTACIDS

11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S)

11.2.1.1.1.1 OMEPRAZOLE

11.2.1.1.1.2 LANSOPRAZOLE

11.2.1.1.1.3 ESOMEPRAZOLE

11.2.1.1.1.4 OTHERS

11.2.1.1.2 H2 BLOCKERS

11.2.1.1.2.1 CIMETIDINE

11.2.1.1.2.2 FAMOTIDINE

11.2.1.1.2.3 NIZATIDINE

11.2.1.1.2.4 RANITIDINE

11.2.1.1.2.5 OTHERS

11.2.1.2 GASTRIC PROKINETIC GENDERNTS

11.2.1.2.1 MOSAPRIDE CITRATE

11.2.1.2.2 METOCLOPRAMIDE

11.2.1.2.3 CISAPRIDE

11.2.1.2.4 ITOPRIDE HYDROCHLORIDE

11.2.1.2.5 DOMPERIDONE

11.2.1.2.6 OTHERS

11.2.1.3 ANTIBIOTICS

11.2.1.3.1 REFAXIMIN

11.2.1.3.2 AMOXICILLIN

11.2.1.3.3 CLARITHROMYCIN

11.2.1.3.4 METRONIDAZOLE

11.2.1.3.5 LEVOFLOXACIN

11.2.1.3.6 TETRACYCLINE

11.2.1.3.7 OTHERS

11.2.1.4 OTHERS

11.2.2 NON- DRUGS

11.2.2.1 PROBIOTICS

11.2.2.1.1 LACTOBACILLUS

11.2.2.1.2 BIFIDOBACTERIUM

11.2.2.1.3 BACILLUS

11.2.2.1.4 STREPTOCOCCUS

11.2.2.1.5 OTHERS

11.2.2.2 PREBIOTICS

11.3 SURGERY

12 EUROPE DYSPEPSIA DRUG MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERIC

12.3 BRANDED

13 EUROPE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION

13.1 OVERVIEW

13.2 WITHOUT PRESCRIPTION DRUGS

13.3 PRESCRIPTION DRUGS

14 EUROPE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.2.1 TABLETS

14.2.2 CAPSULES

14.3 INJECTABLE

15 EUROPE DYSPEPSIA DRUG MARKET, BY GENDER

15.1 OVERVIEW

15.2 FEMALE

15.2.1 30-50 YEARS

15.2.2 MORE THAN 50 YEARS

15.2.3 AGE LESS THAN 30

15.3 MALE

15.3.1 30-50 YEARS

15.3.2 MORE THAN 50 YEARS

15.3.3 AGE LESS THAN 30

16 EUROPE DYSPEPSIA DRUG MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.2.1 TYPE

16.2.1.1 PUBLIC

16.2.1.2 PRIVATE

16.2.2 TIER

16.2.2.1 TIER 3

16.2.2.2 TIER 2

16.2.2.3 TEIR 1

16.3 CLINICS

16.4 HOMECARE SETTINGS

16.5 SPECIALTY CLINICS

16.6 AMBULATORY CENTERS

16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES

16.8 OTHERS

17 EUROPE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 RETAIL SALES

17.2.1 REATIL PHARMACY

17.2.2 HOSPITAL PHARMACY

17.2.3 ONLINE PHARMACY

17.3 DIRECT TENDER

18 EUROPE DYSPEPSIA DRUG MARKET, BY REGION

18.1 EUROPE

18.1.1 GERMANY

18.1.2 U.K.

18.1.3 ITALY

18.1.4 FRANCE

18.1.5 SPAIN

18.1.6 RUSSIA

18.1.7 SWITZERLAND

18.1.8 TURKEY

18.1.9 BELGIUM

18.1.10 NETHERLANDS

18.1.11 DENMARK

18.1.12 SWEDEN

18.1.13 POLAND

18.1.14 NORWAY

18.1.15 FINLAND

18.1.16 REST OF EUROPE

19 EUROPE DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: EUROPE

20 SWOT ANALYSIS

21 EUROPE DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS

21.1 SANOFI

21.1.1 COMPANY SNAPSHOT

21.1.2 REVENUE ANALYSIS

21.1.3 COMPANY SHARE ANALYSIS

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENT

21.2 LUPIN

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 COMPANY SHARE ANALYSIS

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 MANKIND PHARMA

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 COMPANY SHARE ANALYSIS

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENT

21.4 ASTRAZENECA

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 COMPANY SHARE ANALYSIS

21.4.4 PRODUCT PORTFOLIO

21.4.5 RECENT DEVELOPMENT

21.5 BAYER AG

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 COMPANY SHARE ANALYSIS

21.5.4 PRODUCT PORTFOLIO

21.5.5 RECENT DEVELOPMENT

21.6 ABBOTT

21.6.1 COMPANY SNAPSHOT

21.6.2 REVENUE ANALYSIS

21.6.3 PRODUCT PORTFOLIO

21.6.4 RECENT DEVELOPMENT

21.7 ANI PHARMACEUTICALS, INC.

21.7.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANALYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENT

21.8 AOSAIKANG PHARMACEUTICAL CO., LTD.

21.8.1 COMPANY SNAPSHOT

21.8.2 REVENUE ANALYSIS

21.8.3 PRODUCT PORTFOLIO

21.8.4 RECENT DEVELOPMENT

21.9 ASTERISK LABORATORIES (I) PVT. LTD

21.9.1 COMPANY SNAPSHOT

21.9.2 PRODUCT PORTFOLIO

21.9.3 RECENT DEVELOPMENT

21.1 CADILA PHARMACEUTICALS

21.10.1 COMPANY SNAPSHOT

21.10.2 REVENUE ANALYSIS

21.10.3 COMPANY SHARE ANALYSIS

21.10.4 PRODUCT PORTFOLIO

21.10.5 RECENT DEVELOPMENT

21.11 HANMI PHARM. CO., LTD.

21.11.1 COMPANY SNAPSHOT

21.11.2 REVENUE ANALYSIS

21.11.3 PRODUCT PORTFOLIO

21.11.4 RECENT DEVELOPMENT

21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

21.12.1 COMPANY SNAPSHOT

21.12.2 REVENUE ANALYSIS

21.12.3 PRODUCT PORTFOLIO

21.12.4 RECENT DEVELOPMENT

21.13 OTSUKA PHARMACEUTICAL CO., LTD.

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENT

21.14 PERRIGO COMPANY PLC

21.14.1 COMPANY SNAPSHOT

21.14.2 REVENUE ANALYSIS

21.14.3 PRODUCT PORTFOLIO

21.14.4 RECENT DEVELOPMENT

21.15 PRESTIGE CONSUMER HEALTHCARE, INC.

21.15.1 COMPANY SNAPSHOT

21.15.2 REVENUE ANALYSIS

21.15.3 PRODUCT PORTFOLIO

21.15.4 RECENT DEVELOPMENT

21.16 PROCTER & GAMBLE

21.16.1 COMPANY SNAPSHOT

21.16.2 REVENUE ANALYSIS

21.16.3 PRODUCT PORTFOLIO

21.16.4 RECENT DEVELOPMENT

21.17 RECKITT BENCKISER.

21.17.1 COMPANY SNAPSHOT

21.17.2 REVENUE ANALYSIS

21.17.3 PRODUCT PORTFOLIO

21.17.4 RECENT DEVELOPMENT

21.18 REDHILL BIOPHARMA LTD

21.18.1 COMPANY SNAPSHOT

21.18.2 REVENUE ANALYSIS

21.18.3 PRODUCT PORTFOLIO

21.18.4 RECENT DEVELOPMENT

21.19 SALIX PHARMACEUTICALS OR ITS AFFILIATES (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

21.19.1 COMPANY SNAPSHOT

21.19.2 REVENUE ANALYSIS

21.19.3 PRODUCT PORTFOLIO

21.19.4 RECENT DEVELOPMENT

21.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

21.20.1 COMPANY SNAPSHOT

21.20.2 REVENUE ANALYSIS

21.20.3 PRODUCT PORTFOLIO

21.20.4 RECENT DEVELOPMENTS

21.21 WOODWARD PHARMA

21.21.1 COMPANY SNAPSHOT

21.21.2 PRODUCT PORTFOLIO

21.21.3 RECENT DEVELOPMENT

21.22 ZERIA PHARMACEUTICAL CO., LTD.

21.22.1 COMPANY SNAPSHOT

21.22.2 REVENUE ANALYSIS

21.22.3 PRODUCT PORTFOLIO

21.22.4 RECENT DEVELOPMENT

22 QUESTIONNAIRE

23 RELATED REPORTS

Tabellenverzeichnis

 

TABLE 1 EUROPE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 2 EUROPE NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 EUROPE ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 EUROPE DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 5 EUROPE OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 EUROPE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 EUROPE MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 EUROPE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 EUROPE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 EUROPE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 11 EUROPE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 EUROPE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 EUROPE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 EUROPE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 15 EUROPE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 16 EUROPE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 EUROPE SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 EUROPE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 19 EUROPE GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 EUROPE BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 EUROPE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 22 EUROPE WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 23 EUROPE PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 EUROPE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 25 EUROPE ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 EUROPE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 27 EUROPE INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 EUROPE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 29 EUROPE FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 EUROPE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 31 EUROPE MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 EUROPE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 33 EUROPE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 34 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 35 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 36 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 37 EUROPE CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 EUROPE HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 EUROPE SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 EUROPE AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 EUROPE ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 EUROPE OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 43 EUROPE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 44 EUROPE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 EUROPE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 46 EUROPE DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 47 EUROPE DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 48 EUROPE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 EUROPE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 EUROPE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 51 EUROPE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 EUROPE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 EUROPE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 EUROPE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 55 EUROPE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 56 EUROPE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 57 EUROPE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 EUROPE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 59 EUROPE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 EUROPE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 61 EUROPE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 62 EUROPE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 63 EUROPE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 64 EUROPE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 65 EUROPE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 66 EUROPE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 67 EUROPE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 68 EUROPE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 69 EUROPE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 70 EUROPE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 71 EUROPE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 72 EUROPE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 73 EUROPE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 74 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 75 EUROPE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 76 EUROPE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 77 EUROPE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 78 GERMANY DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 79 GERMANY DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 GERMANY MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 GERMANY DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 GERMANY ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 83 GERMANY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 84 GERMANY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 85 GERMANY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 86 GERMANY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 87 GERMANY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 88 GERMANY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 89 GERMANY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 90 GERMANY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 91 GERMANY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 92 GERMANY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 93 GERMANY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 94 GERMANY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 95 GERMANY NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 96 GERMANY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 97 GERMANY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 98 GERMANY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 99 GERMANY DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 100 GERMANY DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 101 GERMANY DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 102 GERMANY ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 103 GERMANY DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 104 GERMANY FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 105 GERMANY MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 106 GERMANY DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 107 GERMANY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 108 GERMANY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 109 GERMANY DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 110 GERMANY RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 111 U.K. DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 U.K. DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 113 U.K. MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 U.K. DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 115 U.K. ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 116 U.K. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 117 U.K. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 118 U.K. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 119 U.K. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 120 U.K. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 121 U.K. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 122 U.K. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 123 U.K. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 124 U.K. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 125 U.K. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 126 U.K. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 127 U.K. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 128 U.K. NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 129 U.K. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 130 U.K. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 131 U.K. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 132 U.K. DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 U.K. BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 134 U.K. DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 135 U.K. DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 136 U.K. ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 137 U.K. DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 138 U.K. FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 139 U.K. MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 140 U.K. DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 141 U.K. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 142 U.K. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 143 U.K. DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 144 U.K. RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 145 ITALY DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 ITALY DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 147 ITALY MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 ITALY DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 149 ITALY ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 ITALY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 ITALY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 152 ITALY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 153 ITALY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 ITALY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 155 ITALY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 156 ITALY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 ITALY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 158 ITALY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 159 ITALY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 ITALY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 161 ITALY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 162 ITALY NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 163 ITALY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 164 ITALY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 165 ITALY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 166 ITALY DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 ITALY DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 168 ITALY DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 169 ITALY ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 170 ITALY DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 171 ITALY FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 172 ITALY MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 173 ITALY DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 174 ITALY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 175 ITALY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 176 ITALY DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 177 ITALY RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 178 FRANCE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 179 FRANCE DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 180 FRANCE MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 FRANCE DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 FRANCE ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 183 FRANCE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 184 FRANCE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 185 FRANCE PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 186 FRANCE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 FRANCE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 188 FRANCE H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 189 FRANCE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 190 FRANCE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 191 FRANCE GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 192 FRANCE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 FRANCE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 194 FRANCE ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 195 FRANCE NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 196 FRANCE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 FRANCE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 198 FRANCE PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 199 FRANCE DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 200 FRANCE DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 201 FRANCE DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 202 FRANCE ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 203 FRANCE DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 204 FRANCE FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 205 FRANCE MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 206 FRANCE DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 207 FRANCE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 208 FRANCE HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 209 FRANCE DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 210 FRANCE RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 211 SPAIN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 212 SPAIN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 SPAIN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 SPAIN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 SPAIN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 216 SPAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 217 SPAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 218 SPAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 219 SPAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 SPAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 221 SPAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 222 SPAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 223 SPAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 224 SPAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 225 SPAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 226 SPAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 227 SPAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 228 SPAIN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 229 SPAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 230 SPAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 231 SPAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 232 SPAIN BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 233 SPAIN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 234 SPAIN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 235 SPAIN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 236 SPAIN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 237 SPAIN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 238 SPAIN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 239 SPAIN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 240 SPAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 241 SPAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 242 SPAIN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 243 SPAIN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 244 RUSSIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 RUSSIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 RUSSIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 247 RUSSIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 248 RUSSIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 249 RUSSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 250 RUSSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 251 RUSSIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 252 RUSSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 253 RUSSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 254 RUSSIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 255 RUSSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 256 RUSSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 257 RUSSIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 258 RUSSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 259 RUSSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 260 RUSSIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 261 RUSSIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 262 RUSSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 263 RUSSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 264 RUSSIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 265 RUSSIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 266 RUSSIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 267 RUSSIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 268 RUSSIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 269 RUSSIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 270 RUSSIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 271 RUSSIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 272 RUSSIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 273 RUSSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 274 RUSSIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 275 RUSSIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 276 RUSSIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 277 SWITZERLAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 278 SWITZERLAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 279 SWITZERLAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 280 SWITZERLAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 SWITZERLAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 282 SWITZERLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 283 SWITZERLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 284 SWITZERLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 285 SWITZERLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 286 SWITZERLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 287 SWITZERLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 288 SWITZERLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 289 SWITZERLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 290 SWITZERLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 291 SWITZERLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 292 SWITZERLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 293 SWITZERLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 294 SWITZERLAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 295 SWITZERLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 296 SWITZERLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 297 SWITZERLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 298 SWITZERLAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 299 SWITZERLAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 300 SWITZERLAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 301 SWITZERLAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 302 SWITZERLAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 303 SWITZERLAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 304 SWITZERLAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 305 SWITZERLAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 306 SWITZERLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 307 SWITZERLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 308 SWITZERLAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 309 SWITZERLAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 310 TURKEY DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 311 TURKEY DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 312 TURKEY MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 313 TURKEY DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 314 TURKEY ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 315 TURKEY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 316 TURKEY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 317 TURKEY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 318 TURKEY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 319 TURKEY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 320 TURKEY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 321 TURKEY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 322 TURKEY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 323 TURKEY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 324 TURKEY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 325 TURKEY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 326 TURKEY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 327 TURKEY NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 328 TURKEY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 329 TURKEY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 330 TURKEY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 331 TURKEY DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 332 TURKEY DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 333 TURKEY DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 334 TURKEY ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 335 TURKEY DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 336 TURKEY FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 337 TURKEY MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 338 TURKEY DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 339 TURKEY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 340 TURKEY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 341 TURKEY DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 342 TURKEY RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 343 BELGIUM DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 344 BELGIUM DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 345 BELGIUM MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 346 BELGIUM DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 347 BELGIUM ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 348 BELGIUM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 349 BELGIUM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 350 BELGIUM PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 351 BELGIUM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 352 BELGIUM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 353 BELGIUM H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 354 BELGIUM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 355 BELGIUM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 356 BELGIUM GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 357 BELGIUM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 358 BELGIUM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 359 BELGIUM ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 360 BELGIUM NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 361 BELGIUM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 362 BELGIUM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 363 BELGIUM PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 364 BELGIUM DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 365 BELGIUM DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 366 BELGIUM DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 367 BELGIUM ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 368 BELGIUM DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 369 BELGIUM FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 370 BELGIUM MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 371 BELGIUM DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 372 BELGIUM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 373 BELGIUM HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 374 BELGIUM DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 375 BELGIUM RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 376 NETHERLANDS DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 377 NETHERLANDS DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 378 NETHERLANDS MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 379 NETHERLANDS DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 380 NETHERLANDS ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 381 NETHERLANDS PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 382 NETHERLANDS PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 383 NETHERLANDS PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 384 NETHERLANDS H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 385 NETHERLANDS H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 386 NETHERLANDS H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 387 NETHERLANDS GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 388 NETHERLANDS GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 389 NETHERLANDS GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 390 NETHERLANDS ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 391 NETHERLANDS ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 392 NETHERLANDS ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 393 NETHERLANDS NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 394 NETHERLANDS PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 395 NETHERLANDS PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 396 NETHERLANDS PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 397 NETHERLANDS DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 398 NETHERLANDS DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 399 NETHERLANDS DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 400 NETHERLANDS ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 401 NETHERLANDS DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 402 NETHERLANDS FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 403 NETHERLANDS MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 404 NETHERLANDS DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 405 NETHERLANDS HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 406 NETHERLANDS HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 407 NETHERLANDS DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 408 NETHERLANDS RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 409 DENMARK DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 410 DENMARK DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 411 DENMARK MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 412 DENMARK DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 413 DENMARK ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 414 DENMARK PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 415 DENMARK PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 416 DENMARK PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 417 DENMARK H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 418 DENMARK H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 419 DENMARK H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 420 DENMARK GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 421 DENMARK GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 422 DENMARK GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 423 DENMARK ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 424 DENMARK ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 425 DENMARK ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 426 DENMARK NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 427 DENMARK PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 428 DENMARK PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 429 DENMARK PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 430 DENMARK DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 431 DENMARK DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 432 DENMARK DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 433 DENMARK ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 434 DENMARK DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 435 DENMARK FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 436 DENMARK MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 437 DENMARK DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 438 DENMARK HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 439 DENMARK HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 440 DENMARK DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 441 DENMARK RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 442 SWEDEN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 443 SWEDEN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 444 SWEDEN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 445 SWEDEN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 446 SWEDEN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 447 SWEDEN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 448 SWEDEN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 449 SWEDEN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 450 SWEDEN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 451 SWEDEN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 452 SWEDEN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 453 SWEDEN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 454 SWEDEN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 455 SWEDEN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 456 SWEDEN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 457 SWEDEN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 458 SWEDEN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 459 SWEDEN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 460 SWEDEN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 461 SWEDEN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 462 SWEDEN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 463 SWEDEN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 464 SWEDEN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 465 SWEDEN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 466 SWEDEN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 467 SWEDEN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 468 SWEDEN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 469 SWEDEN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 470 SWEDEN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 471 SWEDEN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 472 SWEDEN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 473 SWEDEN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 474 POLAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 475 POLAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 476 POLAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 477 POLAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 478 POLAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 479 POLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 480 POLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 481 POLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 482 POLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 483 POLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 484 POLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 485 POLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 486 POLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 487 POLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 488 POLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 489 POLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 490 POLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 491 POLAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 492 POLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 493 POLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 494 POLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 495 POLAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 496 POLAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 497 POLAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 498 POLAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 499 POLAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 500 POLAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 501 POLAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 502 POLAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 503 POLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 504 POLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 505 POLAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 506 POLAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 507 NORWAY DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 508 NORWAY DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 509 NORWAY MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 510 NORWAY DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 511 NORWAY ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 512 NORWAY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 513 NORWAY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 514 NORWAY PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 515 NORWAY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 516 NORWAY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 517 NORWAY H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 518 NORWAY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 519 NORWAY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 520 NORWAY GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 521 NORWAY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 522 NORWAY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 523 NORWAY ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 524 NORWAY NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 525 NORWAY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 526 NORWAY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 527 NORWAY PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 528 NORWAY DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 529 NORWAY DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 530 NORWAY DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 531 NORWAY ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 532 NORWAY DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 533 NORWAY FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 534 NORWAY MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 535 NORWAY DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 536 NORWAY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 537 NORWAY HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 538 NORWAY DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 539 NORWAY RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 540 FINLAND DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 541 FINLAND DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 542 FINLAND MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 543 FINLAND DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 544 FINLAND ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 545 FINLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 546 FINLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 547 FINLAND PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 548 FINLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 549 FINLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 550 FINLAND H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 551 FINLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 552 FINLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 553 FINLAND GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 554 FINLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 555 FINLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 556 FINLAND ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 557 FINLAND NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 558 FINLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 559 FINLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 560 FINLAND PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 561 FINLAND DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 562 FINLAND DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 563 FINLAND DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 564 FINLAND ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 565 FINLAND DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 566 FINLAND FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 567 FINLAND MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 568 FINLAND DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 569 FINLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 570 FINLAND HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 571 FINLAND DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 572 FINLAND RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 573 REST OF EUROPE DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

Abbildungsverzeichnis

FIGURE 1 EUROPE DYSPEPSIA DRUG MARKET: SEGMENTATION

FIGURE 2 EUROPE DYSPEPSIA DRUG MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE DYSPEPSIA DRUG MARKET: DROC ANALYSIS

FIGURE 4 EUROPE DYSPEPSIA DRUG MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING

FIGURE 8 EUROPE DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID

FIGURE 11 EUROPE DYSPEPSIA DRUG MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE EUROPE DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030

FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DYSPEPSIA DRUG MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE DYSPEPSIA DRUG MARKET

FIGURE 15 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE, 2022

FIGURE 16 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 17 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 18 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE

FIGURE 19 EUROPE DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022

FIGURE 20 EUROPE DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)

FIGURE 21 EUROPE DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)

FIGURE 22 EUROPE DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE

FIGURE 23 EUROPE DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022

FIGURE 24 EUROPE DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)

FIGURE 25 EUROPE DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 26 EUROPE DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 27 EUROPE DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022

FIGURE 28 EUROPE DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)

FIGURE 29 EUROPE DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)

FIGURE 30 EUROPE DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE

FIGURE 31 EUROPE DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 32 EUROPE DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 33 EUROPE DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 34 EUROPE DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 EUROPE DYSPEPSIA DRUG MARKET: BY GENDER, 2022

FIGURE 36 EUROPE DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)

FIGURE 37 EUROPE DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 EUROPE DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 EUROPE DYSPEPSIA DRUG MARKET: BY END USER, 2022

FIGURE 40 EUROPE DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 41 EUROPE DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)

FIGURE 42 EUROPE DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 EUROPE DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 44 EUROPE DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 45 EUROPE DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 46 EUROPE DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 EUROPE DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)

FIGURE 48 EUROPE DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)

FIGURE 49 EUROPE DYSPEPSIA DRUG MARKET: BY COUNTRY (2023 & 2030)

FIGURE 50 EUROPE DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)

FIGURE 51 EUROPE DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)

FIGURE 52 EUROPE DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)

Detaillierte Informationen anzeigen Right Arrow

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The Europe Dyspepsia Drug Market is projected to grow at a CAGR of 4.7% during the forecast period by 2030.
The Europe Dyspepsia Drug Market is segmented on the basis of type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel.
The major players in the Europe Dyspepsia Drug Market are Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others.
The countries covered in the Europe Dyspepsia Drug Market are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Denmark, Sweden, Poland, Norway, Finland, and Rest of Europe.